Business
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n  Automation enabled Provista to conduct over 7,600 PCR tests for the month of October, more than in the first 8 months of 2021 combinedCompany sees expanding testing for COVID PCR, neutralizing antibody and flu a&b/RSV opportunities leading to a marked increase in revenue in the coming quartersCompany to present at the GCFF Virtual Conference 2021 Main Event on Thursday November 4, 2021 New York, NY, and Tel Aviv, ISRAEL, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its wholly-owned high complexity CLIA/CAP certified laboratory Provista Diagnostics is seeing a significant ramp up in PCR testing volume with its new automation in place. Concurrent with this announcement, the Company announced that President & CEO Gerald Commissiong is presenting at the GCFF Virtual Conference 2021 Main Event at 2:20pm ET / 11:20pm PT with registration available at https://gcff-nov-2021.eventbrite.ca/?aff=TOMDF . Todos completed automation installation in Q3 2021 and began ramping up sales efforts heading into Q4.  James Doherty was hired in Q3/21 as Senior Director of Business Development to help drive growth.  This led to a significant increase in testing volume in October.  With reimbursement rates of up to $130 per test, and large volume reference work available, PCR testing capacity at Provista today stands 10,000 tests per day, with capacity expected to approach 20,000 tests by the end of November as the Company begins to hire additional lab staff to meet customer demands. We believe PCR testing represents a significant financial opportunity for Todos heading into 2022.   “We are very excited about the pace of COVID PCR testing volume growth at Provista thus far in the fourth quarter of 2021,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We are just beginning to scratch the surface of what is possible in regards to our automation strategy at Provista. Our new sales team is energized and looking to drive growth by expanding our marketing efforts and broadening our testing suite of products.  There has been a heightened focus on the cPass neutralizing antibody testing that is becoming more relevant as pediatric...